Sixty Degree Capital
Venture capitalNorth York · Pre-Seed–Late Stage · 16 people tracked
Investment thesis
Sixty Degree Capital pursues a thesis-driven strategy across healthcare and technology, seeking breakthrough opportunities capable of reshaping industries. Its technical team combines domain expertise, rigorous quantitative analysis, and hands-on operational support to identify the underlying trends driving durable, transformational change. In technology it targets AI, cybersecurity, digital infrastructure, and SaaS; in healthcare it covers drug development, diagnostics, digital health, and medical devices. The firm invests across stages from pre-seed to growth and emphasizes purposeful innovation, forward-thinking, precision, and transparency, while also channeling a portion of proceeds toward educational institutions, hospitals, and community organizations.
Source: firm website, verified Aug 3, 2026.
Team · 16 people
from the firm's website & curated
What they invest in
from 15 of 25 portfolio companiesHealthtech ×10Biotech ×9AI & Machine Learning ×4Enterprise Software ×4Cloud Computing ×2Cybersecurity ×2Digital Health ×2Wellness & Fitness ×2
HQs:United States×8Germany×1Israel×1
Who they back
founder profiles across 10 portfolio companiesFounding team size:solo founder×42 founders×23 founders×4
Investments · 25 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 12020 · 14 dated
Cyber Fund III portfolio company that completed an initial public offering.
Herndon, US
Christopher Bradley DeMay(Executive Officer)Jaye Alison Alfers(Executive Officer)Simon Mark Davidson(Director)John Sheldon Serafini(Executive Officer, Director)inArthur Lewis Money(Director)David Farnsworth(Director)
Co-investorsCenter15 CapitalGula Tech AdventuresHemisphere Ventures LLCIceNineManhattan Venture PartnersNew North Ventures+7 more
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystNextech Invest+5 more
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)in
Co-investorsJeito CapitalSanofi VenturesSofinnova PartnersVIVES PartnersApollo Health Ventures
Clinical-stage gene therapy company developing AAV therapeutics for inherited retinal disorders.
Co-investorsLongwood FundXGEN Venture
Clinical-stage biotech developing dual-acting biologics for sustainable weight loss and maintenance.
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)
BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSamsara BioCapitalSolasta VenturesSR One Capital Management+2 more
Cato Networks provides a cloud-native SASE platform that converges networking, zero-trust security, and access into a single global service for enterprises.
Cloud ComputingCybersecurityEnterprise SoftwareTel Aviv, IL
Shlomo Kramer(Co-Founder and CEO)Gur Shatz(Co-Founder and Board Member)Tomer Wald(Chief Financial Officer)Alon Alter(Chief Business Officer)Zehorit Mulshanski(Chief People Officer)Eyal Heiman(Chief Technology Officer)
Co-investorsAcrew CapitalAdams Street PartnersArcher Capital GroupArcher Venture CapitalAspect VenturesBallistic Ventures+8 more
Clinical-stage biotech developing TCR-mimetics recognizing intracellular tumor antigens for hematological and solid cancers.
Eclypsium provides hardware and firmware security solutions for enterprises to identify and address vulnerabilities in chips, low-level code, and digital supply chains.
CybersecurityDefense TechEnterprise SoftwareHardwarePortland, US
Yuriy Bulygin(Co-founder)Alex Bazhaniuk(Co-founder)Alex B(Founder)John Ewert(Executive Officer)
BoardAlex Doll(Director)inTimothy Porter(Director)in
Co-investorsAlumni VenturesAndreessen HorowitzAV8 VenturesaVentureBasecamp FundDnipro+13 more
Chicago, US
Edward Bellis(Executive Officer, Director)Michael Roytman(Director)inJason Jacobs(Executive Officer)Stephen Ward(Director)
BoardJohn Cowgill(Director)in
Co-investorsCostanoa VenturesHyde Park Angels
Oncology-focused pharmaceutical company developing first-in-class nuclear export inhibitors for cancer treatment.
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSofinnova PartnersAgent Capital+1 more
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.
BiotechHealthtechMedfield, US
Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)Robert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)
Co-investors5AM VenturesAtlas VentureRA CapitalEQT Life SciencesVivo CapitalGimv+1 more
KnownWell provides virtual and in-person weight-inclusive healthcare for patients with overweight and obesity.
Digital HealthHealthtechWellness & FitnessNeedham, US
Ben Wanamaker(Director)Angela Fitch(Executive Officer)inBrooke Boyarsky Pratt(Executive Officer, Director)in
BoardVineeta Agarwala(Director)inIan Chiang(Director)in
Co-investorsAndreessen HorowitzCVS Health VenturesFlare Capital Partners
Digital asset exchange platform offering trading, derivatives, and institutional services with strong security and regulatory compliance.
Marathon Health provides an advanced primary care model to employers through onsite, nearsite, network, and virtual health centers, aiming to improve employee health and lower healthcare costs.
Digital HealthHealthtechWellness & Fitness
Co-investorsGeneral AtlanticOak HC/FT
Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.
AI & Machine LearningBiotechHealthtech
Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)Darrin Miles(Chief Executive Officer)Philip Komarnitsky(Chief Medical Officer)Tanja Weber(Chief Business Officer)
Co-investorsVersant VenturesForesite CapitalCowen Healthcare InvestmentsGoldman Sachs
NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.
BiotechHealthtechAustin, US
Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)inIvan Cheung(Chief Executive Officer)inLeena Gandhi(Chief Medical Officer)inTatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)
Co-investorsCatalio Capital Management, LPMPM BioImpactSanofi VenturesCatalio Capital ManagementInvusLeaps by Bayer
PandasAI is an open-source library that lets users query data stored in dataframes, databases, or data lakes using natural language to perform analysis and generate visualizations without writing code.
AI & Machine LearningData & InfrastructureEnterprise SoftwareMunich, DE
Gabriele Venturi(Founder)in
Co-investorsEpisode1Runa CapitalY CombinatorVento
Rafay builds infrastructure orchestration and workflow automation software for self-service compute consumption across GPU and CPU environments.
AI & Machine LearningCloud ComputingDeveloper ToolsEnterprise Software
Co-investorsFloodgateForgePoint CapitalMoment Ventures, LlcNTT DOCOMO VenturesRidge Ventures
RedRidge Bio discovers and develops biparatopic antibodies (antibodies that bind two sites on a single protein), including biparatopic antibody-drug conjugates, as therapeutics for oncology and autoimmune diseases.
BiotechHealthtech
Bill Sellers(Scientific Founder and Director Cancer Program, Broad Institute)Stephen Yoder(President & CEO)
Co-investorsNew Enterprise Associates (NEA)Versant Ventures
Biotech company developing next-generation non-viral gene delivery systems.
Space exploration and technology company developing rockets and spacecraft for human spaceflight and satellite deployment.
T-knife develops engineered T cell therapies designed to treat patients with solid tumors, using proprietary platforms and synthetic biology to enhance T cells.
BiotechHealthtech
Elisa Kieback(Founder)in
Co-investorsAndera PartnersRA CapitalVersant VenturesFidelity Investments
Marwan Forzley(Founder)in
Co-investorsBY Venture PartnersDASH VenturesDigital Currency GroupElectric Feel Ventures LlcKleiner PerkinsNyca+3 more
Exits · 2
IPOs and acquisitions across the tracked portfolioHawkEye 360NYSE: HAWKParabilis MedicinesNASDAQ: PBLS
Portfolio news
latest coverage across their companiesHawkEye 360 · finance.yahoo.com · Aug 15, 2026
Arcellx · biobuzz.io · Aug 14, 2026
Cato Networks · Cato Networks · Aug 3, 2026
Empirical Security · theaiinsider.tech · Jul 29, 2026
Rafay · finance.yahoo.com · Jul 9, 2026
Parabilis Medicines · pharmexec.com · Jun 19, 2026
Frequently asked questions
- How many investments has Sixty Degree Capital made?
- Sixty Degree Capital has 23 tracked investments, 1 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.
- What stage does Sixty Degree Capital invest at?
- Sixty Degree Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Sixty Degree Capital focus on?
- Sixty Degree Capital focuses on AI & Machine Learning, Biotech, Cloud Computing, Cybersecurity, Data & Infrastructure, Developer Tools, Digital Health, Enterprise Software, Fintech, Healthtech, Medical Devices, SaaS.
- Where is Sixty Degree Capital located?
- Sixty Degree Capital is headquartered in North York, CA.
- Does Sixty Degree Capital lead rounds?
- Sixty Degree Capital typically participates in rounds rather than leading them.
- Who does Sixty Degree Capital co-invest with?
- Sixty Degree Capital most often shares deals with RA Capital, 5AM Ventures, Andreessen Horowitz, among 84 tracked co-investors.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.